Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
REFERENCES 1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health careassociated infections. N Engl J Med. 2014;370:1198-208. 2. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317. 3. Arendrup, Maiken C. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010; 16:445-452. 4. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373:1445-1456. 5. Cuenca-Estmella, M, et al. Verweij PE, Arendrup MC, et al; SCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;7:9-18. 6. Pini P, Bettua C, Orsi C. Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. Infection. 2015 Oct 16. [Epub ahead of print] 7. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. Clin Infect Dis. 2015;60:892899. 8. Lefort A, Chartier L, Sendid B, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18:e99-e109. 9. Andes DR, Safdar N, Baddley JW, et al; the Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive Candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110-1122. 10. Pappas PG, Kaufmann CA, Andes D, et al. Clinical Practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535. 11. Reboli AC, Rotstein C, PG Pappas, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-2482. 12. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995;155:2429-2435. 13. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001;33:1959-1967. 14. Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51:295-303. 15. S Kucharikova, H Tournu, M Holtappels, et al. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated candidiasis. Antimicrob Agents Chemother. 2010;54:4474-4475. 16. Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin b lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46:1773-1780. 17. Oude Lashof AM, Rothova A, Sobel JD, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53:262-268. 18. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin b for the treatment of candidemia in patients without neutropenia. Candidemia study group and the national institute. N Engl J Med. 1994;331:1325-1330. 19. Bullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin b followed by fluconazole for candidaemia in non-neutropenic patients: a randomized noninferiority trial. Lancet. 2005;366:1435-1442. 20. Paramythiotou E, Frantzeskaki F, Flevari A, et al. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules. 2014;19:1085-1119. 21. Edwards JE. Candida species. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015:2879-2894. 22. Alvarez-Lerma F, Nolla-Salas J, León C, et al. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med. 2003;29:1069-1076. 23. Simpson C, Blitz S, Shafran SD. The effect of current management on morbidity and mortality in hospitalized adults with funguria. J Infect. 2004;49:248-252. 24. Paul N, Mathai E, Abraham OC, et al. Factors associated with candiduria and related mortality. J Infect. 2007;55:450-455. 25. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The national institute for allergy and infectious diseases (NIAID) mycoses study group. Clin Infect Dis. 2000;30:14-18. 26. Bougnoux ME, Kac G, Aegerter P, et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: Incidence, molecular diversity and outcome. Intensive Care Med. 2008;34:292-299. 27. Binelli CA, Moretti ML, Assis RS, et al. Investigation of the possible association between nosocomial candiduria and candidemia. Clin Microbiol Infect. 2006;12:538-543. 28. Kauffman CA. Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am. 2014;28:61-74. 29. Meersseman W, Lagrou K, Spriet I, et al. Significance of the isolation of candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35:1526-1531. 30. Pappas P, Kaufmann C, Andes D, et al. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-e50.